MedPath

Postoperative Biliary Fistula Prevention After Hepatectomy

Not Applicable
Completed
Conditions
Hepatectomy
Interventions
Procedure: External Biliary duct stent in the bile duct by cystic way
Registration Number
NCT01469442
Lead Sponsor
University Hospital, Toulouse
Brief Summary

Aim : Effect of external biliary duct stent after hepatectomy on the occurence of postoperative biliary fistula.

Methods : French prospective multicenter randomized trial. Population study: Adult patients who underwent hepatectomy (\> 2 segments) on non-cirrhotic liver.

Hypothesis: decreased postoperative biliary fistula from 15% to 5% with the presence of a external biliary duct stent. With this hypothesis, the number of patients required to be equal to 152 per group for a total of 304 patients.

Outcome measure: Primary : Postoperative biliary complications (biliary fistula, biloma, biliary peritonitis) Secondary : All morbidity, mortality, additional manoeuvres to treat biliary fistula, during of hospital stay and biliary fistula.

Follow up: A follow-up of patients 3 months after surgery for all patients. The planned total duration of the study is 3 years and 3 months.

Detailed Description

After performing the hepatectomy and verification of hemostasis, patients were randomized (external biliary duct stent or not) by sealed envelopes. Systematic intraoperative test with methylene blue or air by the external biliary duct stent (EBDS) will necessary for all patients. Intra-abdominal drainage or not and type will be at the discretion of the surgeon. The EBDS will be left open for the first 7 postoperative days and then clamped. The EBDS will be removed during a consultation 5 weeks after surgery. Both groups of patients will be reviewed at 3 months after surgery, it will be noted at this point the possible complications related to the presence of EBDS (leakage from the drain, drop..). If patients are hospitalized more than five weeks, the study will stop at their consultation three months or the day of the consultation where the DTC is removed if it is still present at 3 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
304
Inclusion Criteria
  • Subject has given his informed consent and signed consent
  • Hepatectomy at least 2 segments of liver parenchyma for a benign or malignant disease by laparotomy
  • Not cirrhotic liver
Exclusion Criteria
  • Surgery made in emergency
  • Surgery by laparoscopy
  • Need to draw up a bilic-digestive anastomosis
  • Liver cirrhosis
  • History of cholecystectomy
  • Resection of less than 2 segments
  • Preoperative jaundice (total bilirubin> 30 micromol / l)
  • Presence of preoperative biliary drainage
  • Patients requiring the installation of a drain transcystic during the operation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
external biliary duct stentExternal Biliary duct stent in the bile duct by cystic way'External Biliary duct stent in the bile duct by cystic way'
Primary Outcome Measures
NameTimeMethod
Postoperative biliary fistula3 months after surgey

3 forms of diagnosis : bile in the intra-abdominal drainage; presence of an intra-abdominal collection of bile liquid (biloma); presence of an effusion of bile in the abdominal space (biliary peritonitis).

Secondary Outcome Measures
NameTimeMethod
Morbidity3 months after surgey

additional maneuvers for treat biliary fistula, during of hospital stay, during of biliary fistula

Mortality3 months after surgery

Trial Locations

Locations (11)

Hotel Dieu

馃嚝馃嚪

Nantes, France

H么pital beaujon

馃嚝馃嚪

Clichy, France

Institut Paoli Calmettes

馃嚝馃嚪

Marseille, France

CHU la conception

馃嚝馃嚪

Marseille, France

H么pital St Eloi

馃嚝馃嚪

Montpellier, France

H么pital Claude Huriez

馃嚝馃嚪

Lille, France

H么pital Saint Antoine

馃嚝馃嚪

Paris, France

h么pital Haute Pierre

馃嚝馃嚪

Strasbourg, France

Toulouse Purpan

馃嚝馃嚪

Toulouse, France

H么pital Paul Brousse

馃嚝馃嚪

Villejuif, France

CHU

馃嚝馃嚪

Amiens, France

漏 Copyright 2025. All Rights Reserved by MedPath